Breaking News Bar

Business News and Information

Edge Therapeutics Reports Third Quarter 2018 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the quarter ended September 30, 2018.

Third Quarter Financial Results

Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2018 were $36.8 million, compared with $88.1 million as of December 31, 2017.

Operating Expenses:  Research and development (R&D) expenses decreased to $0.3 million in the third quarter of 2018 from $6.9 million in the third quarter of 2017. The decrease in R&D expense was primarily due to a decrease in expenses related to the previously announced discontinuance of the NEWTON 2 clinical study and reduction in workforce. General and administrative (G&A) expenses decreased to $3.3 million for the three months ended September 30, 2018 from $4.0 million in the comparable period in 2017. The decrease in G&A expense was largely due to decreases in departmental operating expenses, professional fees and marketing costs. In the third quarter of 2018, Edge recorded a restructuring charge of $0.8 million related to the previously announced discontinuance of the NEWTON 2 study.

Net Loss: Net loss for the third quarter ended September 30, 2018 was $4.3 million, including the $0.8 million restructuring charge. Net loss in the third quarter of 2017 was $11.3 million.

Review of Strategic Alternatives

Edge continues to be actively engaged in its review of strategic alternatives to maximize stockholder value, a review that was announced in April 2018. At that time, Edge retained Piper Jaffray & Co. to act as its financial advisor to assist with this review process. Potential strategic alternatives that may be explored or evaluated as part of this review include, but are not limited to, an acquisition, merger, business combination or other strategic transaction involving Edge. Edge has reduced the scope of its operations, including the size of its workforce, in order to preserve its cash resources during the strategic alternatives review process.

There is no defined timeline for completion of the review process. There is no assurance that this review will result in Edge pursuing any transaction or that a transaction, if pursued, will be completed. Edge does not intend to discuss or disclose further developments regarding the strategic review process unless and until its Board of Directors has approved a specific action or otherwise determined that further disclosure is appropriate or required by law.

About Edge Therapeutics, Inc.
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that seeks to discover, develop and commercialize novel therapies capable of transforming treatment paradigms for the management of serious medical conditions. For additional information about Edge, please visit

Forward-Looking Statements

This press release and any statements of representatives of Edge Therapeutics, Inc. related thereto that are not historical in nature contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, without limitation, statements with respect to Edge’s plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," “seeks,” "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of Edge’s management and are subject to significant risks and uncertainties. Actual results may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various risk factors (many of which are beyond Edge's control) as described under the heading "Risk Factors" in Edge’s filings with the United States Securities and Exchange Commission.

Statements of Operations and Comprehensive Loss

 Three Months Ended September 30, Nine Months Ended September 30,
 2018  2017  2018  2017 
Operating expenses:       
Research and development expenses$317,684  $6,913,171  $15,583,565  $23,477,971 
General and administrative expenses 3,286,891   3,990,283   11,303,446   12,365,509 
Restructuring expenses 847,852      7,494,094    
Impairment charges       2,672,581    
Total operating expenses 4,452,427   10,903,454   37,053,686   35,843,480 
Loss from operations (4,452,427)  (10,903,454)  (37,053,686)  (35,843,480)
Other income (expense):           
Interest income 187,256   214,064   696,035   479,297 
Interest expense    (592,089)  (1,425,255)  (1,591,998)
Net loss and comprehensive loss (4,265,171)  (11,281,479)  (37,782,906)  (36,956,181)
Loss per share basic and diluted$(0.14) $(0.37) $(1.21) $(1.23)
Weighted average common shares outstanding basic and diluted 31,328,128   30,852,514   31,198,804   30,091,640 

Balance Sheets

 September 30, 2018 December 31, 2017
Current assets:   
Cash and cash equivalents$36,814,899  $88,067,647 
Prepaid expenses and other current assets 247,182   986,680 
Total current assets 37,062,081   89,054,327 
Property and equipment, net 468,170   3,423,880 
Other assets 142,870   142,870 
Total assets$37,673,121  $92,621,077 
Current liabilities:     
Accounts payable$590,694  $4,369,133 
Accrued expenses 917,871   5,422,205 
Restructuring reserve 5,179,722    
Short term debt    3,075,421 
Total current liabilities 6,688,287   12,866,759 
Noncurrent liability:     
Long term debt    17,382,907 
Preferred stock, 5,000,000  shares authorized at September 30, 2018 and December 31, 2017, 0 outstanding     
Common stock, $ 0.00033 par value, 75,000,000 shares authorized at September 30, 2018 and December 31, 2017, 31,328,128 shares and 30,869,205 shares issued and outstanding at September 30, 2018 and  December 31, 2017, respectively 10,551   10,400 
Additional paid-in capital 220,705,548   214,309,370 
Accumulated deficit (189,731,265)  (151,948,359)
Total stockholders' equity 30,984,834   62,371,411 
Total liabilities and stockholders' equity$37,673,121  $92,621,077 


Investor and Media Contact:
Gregory Gin
Edge Therapeutics, Inc.
Tel: 1-800-208-EDGE (3343)

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear